Association Between Proton Pump Inhibitor Use and Anemia: A Retrospective Cohort Study
- EvoluciÃ³n epidemiolÃ³gica de la enfermedad Ã¡cido pÃ©ptica en un Centro de endoscopia diagnÃ³stica de BogotÃ¡ entre 1993 y 2007. Arango, Luis Alberto Ángel; Boada, Diego Gómez; Díaz, María Paula Villalba // Revista Colombiana de GastroenterologÃa;Jun2010, Vol. 25 Issue 2, p139
Objective: To describe epidemiological characteristics of individuals suffering from acid peptic disease found by a first level endoscopic diagnostic center from 1993 and 2007. Methods: A retrospective, descriptive and analytical study of series of patients. Results: 12,638 registers were...
- Rabeprazole: quest for the best PPI. Sugano, Kentaro // Journal of Gastroenterology;2002, Vol. 37 Issue 3, p233
Editorial. Comments on an article dealing with the effects of proton pump inhibitors (PPI) rabeprazole and omeprazole on parietal cells and other acid regulatory cells in the rat stomach. Details on the study; Background on PPI; Recommendations.
- Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Tsai, Yi-Wen; Wen, Yu-Wen; Huang, Weng-Foung; Chen, Pei-Fen; Kuo, Ken; Hsiao, Fei-Yuan // Journal of Gastroenterology;Jan2011, Vol. 46 Issue 1, p39
Background: Concomitant use of antiplatelet agents and proton-pump inhibitors (PPIs) has been recommended in patients with a history of gastrointestinal (GI) hemorrhage. However, recent studies have reported that PPIs may alter clopidogrel's pharmacokinetics and potentially lead to an increased...
- GI Cancer Associated with Iron Deficiency Anemia. Shaughnessy, Allen // American Family Physician;3/15/2003, Vol. 67 Issue 6, p1339
Discusses the study 'Iron Deficiency and Gastrointestinal Malignancy: A Population-based Cohort Study,' by G. Ioannou et al., from the September 2002 issue of the 'American Journal of Medicine.'
- A PROSPECTIVE AUDIT OF FAST TRACK NURSE LED EVALUATION OF THE GASTROINTESTINAL TRACT IN PATIENTS WITH IRON DEFICIENCY ANAEMIA. Georghegan, M.; Kumar, S.; Bowler, L.; Ishaq, S.; Singh P., P. // Gut;Apr2003 Supplement 1, Vol. 52, pA109
Introduction: Iron deficiency anaemia (IDA) is often not approprib ately investigated. Incomplete work up and unacceptable delay in its investigation may lead to poor outcome. Methods: General practitioners and consultants were offered a nurse led, fast track service for gastrointestinal...
- Pantoprazole. Smith, Candace // Formulary;Jan2000, Vol. 35 Issue 1, p28
Pantoprazole is an irreversible proton pump inhibitor that effectively reduces gastric acid secretion. In clinical trials, pantoprazole has been well tolerated and efficacious in the treatment of both duodenal and gastric ulcers as well as gastroesophageal reflux disease. Preliminary results...
- Newest proton pump inhibitor approved for gastrointestinal ills. Portyansky, Elena // Drug Topics;9/20/99, Vol. 143 Issue 18, p29
Presents information on the proton pump inhibitor (PPI) Aciphex (rabeprazole sodium) for gastrointestinal ills. Features of the drug; Problems with the other PPI; Result of the clinical trial of the drug.
- Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children. Scott, L.J. // Pediatric Drugs;2003, Vol. 5 Issue 1, p57
â–´ Lansoprazole, a proton pump inhibitor, inactivates the H/K-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. â–´ After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at...
- The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits. Salim Bastaki; Irwin Chandranath; Jaipaul Singh // Molecular & Cellular Biochemistry;Feb2008, Vol. 309 Issue 1/2, p167
AbstractÃ‚Â Ã‚Â Proton pump inhibitors (PPIs) are widely used to treat hyperacid secretion and stomach ulcers. The study investigated the anti-secretory and anti-ulcer effects of esomeprazole, the S-isomer of omeprazole on dimaprit, histamine and dibutyryl adenosine 3, 5 cyclic...